Research programme: viral vaccines - Valneva

Drug Profile

Research programme: viral vaccines - Valneva

Alternative Names: Metapneumovirus vaccine - Valneva; Yellow fever vaccine - Valneva

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Valneva
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Yellow fever
  • Research Metapneumovirus infections

Most Recent Events

  • 09 Nov 2017 Valneva plans a phase I trial for VLA 1553 for Chikungunya virus infections (Prevention, In volunteers) in USA (IM) (NCT03382964) in early 2018
  • 09 Nov 2017 Valneva and Emergent BioSolutions plan a phase I trial for VLA 1601 for Zika virus infection (In volunteers, Prevention) in USA in early 2018 (NCT03425149)
  • 26 Jul 2017 Emergent BioSolutions in-licenses ZIKV technology from Valneva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top